Loading...

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?: Expert Opinion on Biological Therapy

INTRODUCTION: Monoclonal antibodies (mAbs) targeting checkpoint inhibitors have demonstrated clinical benefit in treating patients with cancer and have paved the way for additional immune-modulating mAbs such as those targeting costimulatory receptors. The full clinical utility of these agents, howe...

Full description

Saved in:
Bibliographic Details
Published in:Expert Opin Biol Ther
Main Authors: Ryan, Joseph M., Wasser, Jeffrey S., Adler, Adam J., Vella, Anthony T.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4955764/
https://ncbi.nlm.nih.gov/pubmed/26855028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14712598.2016.1152256
Tags: Add Tag
No Tags, Be the first to tag this record!